A single-center, retrospective cohort study was conducted to assess response to treatment and progression of disease in patients with severe lymphopenia undergoing treatment with immune checkpoint inhibitors for NSCLC.
A team of international investigators deployed a survey to understand the needs of patients with EGFR-positive lung cancer community.
Although patient-reported outcomes measures were similar with lorlatinib and crizotinib in non-small cell lung cancer, more patients reported improvement in symptoms with lorlatinib.
The addition of durvalumab after chemoradiotherapy for treatment of stage III NSCLC was cost-effective compared with chemoradiotherapy alone.
Study data presented at the 2020 World Conference on Lung Cancer in Singapore illustrate the utility of a 10-marker methylation panel in lung cancer.
Dean Fennell, MBBS, PhD, presented data from a preliminary analysis of the phase 3 CONFIRM trial at the 2020 World Conference on Lung Cancer in Singapore.
The aim of the phase 3 J-AXEL trial was to confirm nab-paclitaxel’s noninferiority to docetaxel in patients with previously treated non-small cell lung cancer (NSCLC).
Investigators evaluated the safety and feasibility of microcoil in simultaneous localization for multiple pulmonary nodules before video-assisted thoracic surgery (VATS).
This study characterizes the effect of corticosteroid use for immune-related adverse event (irAE) management on survival in patients with non-small cell lung cancer who received immune checkpoint inhibitor therapy.
This retrospective study reviewed small cell transformation (SCT) cases from the past 2 years to investigate the phenomenon of pseudo-SCT.
